Conflict of interest: Nothing to report.
Intensive short-term chemotherapy regimen induces high remission rate (over 90%) and event-free survival both in children and adult patients with advanced sporadic Burkitt lymphoma/leukemia†
Article first published online: 16 NOV 2011
Copyright © 2011 Wiley Periodicals, Inc.
American Journal of Hematology
Volume 87, Issue 1, pages 22–25, January 2012
How to Cite
Todeschini, G., Bonifacio, M., Tecchio, C., Balter, R., Carli, G., Stefani, P. M., Adami, F., Zamò, A., Tos, A. P. D., Marino, F., Gherlinzoni, F., Marradi, P., Semenzato, G. and Pizzolo, G. (2012), Intensive short-term chemotherapy regimen induces high remission rate (over 90%) and event-free survival both in children and adult patients with advanced sporadic Burkitt lymphoma/leukemia. Am. J. Hematol., 87: 22–25. doi: 10.1002/ajh.22189
- Issue published online: 16 DEC 2011
- Article first published online: 16 NOV 2011
- Accepted manuscript online: 13 SEP 2011 08:37PM EST
- Manuscript Accepted: 10 SEP 2011
- Manuscript Received: 5 SEP 2011
The optimal treatment of advanced sporadic Burkitt lymphoma in adults is still a matter of debate. The salutary results of pediatric therapies did open the road for improving the adult outcome. Between May 1988 and March 2009, 71 consecutive patients—46 adults, 25 children—affected by Burkitt lymphoma/leukemia were treated with the same intensive pediatric protocol alternating vincristine, adriamycine and fractionated ciclophosphamide (phase A) with high dose methotrexate and high dose cytarabine (phase B) in four Italian institutions. Eighty-nine per cent of patients were in Stage III–IV or had L3 leukemia. Complete remissions were 67/71 (94.4%), 24/25 (96%) in children, and 43/46 (93.5%) in adults. Toxic deaths were 3/71 (4.2%), all in adults. There were nine relapses (one in children, eight in adults), all but one observed early. After a median observation of 94 months (range 23–275), the Event–Free Survival rate is 92% in children and 71.7% in adults (P = 0.067). The 23 more recent adults received also rituximab, without differences in outcome as compared to patients who did not. Our experience confirms that such an intensive pediatric-derived chemotherapy is feasible and improves the long-term outcome of adults with advanced Burkitt lymphoma. Am. J. Hematol., 2012. © 2011 Wiley Periodicals, Inc.